Headquartered in Malvern, PA·Fiscal year ends December·NYSE: ANVS·annovisbio.com
About Annovis Bio
Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage, pre-revenue biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.
Its lead candidate, buntanetap (formerly posiphen), is an investigational once-daily oral small molecule. It inhibits the translation of multiple neurotoxic proteins through a specific RNA-targeting mechanism. These proteins include APP and amyloid beta, tau, alpha-synuclein, and TDP-43.
The company's main programs are:
- **DUET-AD:** a fully enrolled 862-patient pivotal Phase 3 trial in early Alzheimer's. It has two prespecified readouts: a 6-month symptomatic readout expected in March 2027 and an 18-month disease-modifying readout.
- **OLE-AD:** an Alzheimer's open-label extension study.
- **OLE-PD:** a 36-month Parkinson's open-label extension study with 326 patients enrolled.
Annovis is preparing a New Drug Application with support from AI regulatory partner Weave Bio. It funds operations through equity offerings, most recently a public offering of approximately $21.0 million in gross proceeds closed in November 2026. Updated
Dementia is a major healthcare problem across the globe. It is estimated by medical professionals that someone develops some form of dementia every three seconds, and about 55-60 million people currently suffer…
Annovis Bio, Inc. (NYSE: ANVS) is a Phase 3 clinical-stage, pre-revenue biotechnology company developing treatments for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Its lead candidate, buntanetap (formerly posiphen), is an investigational once-daily oral small molecule.
What is the ANVS stock price target?
The Wall Street consensus 12-month price target for ANVS is $10.50.